Autor: |
Nealon J; Sanofi Vaccines, Lyon, France. Electronic address: joshua.nealon@sanofi.com., Biering-Sørensen T; Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Steno Diabetes Center, Copenhagen, Denmark., Crépey P; Ecole des hautes études en santé publique (EHESP), Université de Rennes, CNRS, IEP Rennes, France., Harris R; Sanofi Vaccines, Lyon, France., Schaberg T; Formerly Centre for Pneumology, Rotenburg, Germany., Chit A; Sanofi Vaccines, Lyon, France; Leslie Dean Faculty of Pharmacy, University of Toronto, Toronto, Canada. |
Abstrakt: |
Competing Interests: Declarations of competing interest AC, RH and JN are full-time employees of Sanofi, a company that makes vaccines including against influenza and hold stocks in the company. PC reports consulting fees unrelated to this project from Sanofi. TS reports consulting fees from Sanofi and honoraria for presentations unrelated to this project. TBS has received research grants from Sanofi Pasteur, GSK, Novo Nordisk, AstraZeneca, Boston Scientific and GE Healthcare, consulting fees from Novo Nordisk, IQVIA, Parexel, Amgen, CSL Seqirus, GSK and Sanofi Pasteur, and lecture fees from Bayer, Novartis, Sanofi Pasteur, GE healthcare and GSK. |